GLP-1受体激动剂对线粒体功能,炎症标志物和白细胞-内皮相互作用在2型糖尿病中的影响
Clara Luna-Marco1, Arantxa M de Marañon2, Alberto Hermo-Argibay1
1Service of Endocrinology and Nutrition, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset, Valencia, Spain.
Redox biology
|August 17, 2023
概括
类似葡萄糖-1受体激动剂 (GLP-1 RA) 改善线粒体功能,减少2型糖尿病 (T2D) 的炎症. 这种治疗还可以降低T2D患者动脉样硬化和心血管疾病风险的标志物.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
背景情况:
- 2型糖尿病 (T2D) 与代谢功能障碍,线粒体功能障碍,炎症以及动脉样硬化和心血管疾病 (CVD) 的风险增加有关.
- 氧化应激和改变的白细胞-内皮相互作用是T2D并发症的关键因素.
研究的目的:
- 在2型糖尿病患者中评估类似葡萄糖-1受体激动剂 (GLP-1 RA) 的治疗效果.
- 评估GLP-1 RA对氧化压力的影响,线粒体功能,白细胞-内皮细胞相互作用,炎症和心动脉内膜-介质厚度 (CIMT).
主要方法:
- 招募了255名T2D患者和175名对照人群,分为GLP-1RA治疗 (59) 和未治疗 (196) 组.
- 测量了多态核白细胞 (PMN) 中的活性氧物种 (ROS) 生产,氧耗和白细胞-内皮细胞相互作用.
- 量化炎症标记物,粘附分子和CIMT.
主要成果:
- GLP-1 RA治疗减少了ROS的产生,改善了线粒体呼吸和膜潜力.
- 白细胞-内皮细胞相互作用被调节,滚动和粘附减少.
- 观察到促炎性标志物 (ICAM-1,VCAM-1,IL-6,TNFα,IL-12) 的水平降低,IL-10的增加. 在GLP-1 RA治疗组中,CIMT显著降低.
结论:
- GLP-1 RA治疗对T2D中的氧化还原平衡和线粒体功能产生了积极的影响.
- 该疗法减少了炎症和白细胞-内皮细胞相互作用,有助于降低动脉样硬化进展.
- 在2型糖尿病患者中,GLP-1 RA疗法有可能减轻心血管风险.
相关概念视频
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K


